Jacob Rubens, Quotient Therapeutics CEO
August 28, 2024 06:30 AM EDT
Startups
Deals
R&D

Pfiz­er part­ners with Flag­ship ge­net­ics start­up Quo­tient on heart and kid­ney drugs

Ryan Cross

Senior Science Correspondent

Pfiz­er has struck its sec­ond part­ner­ship with a Flag­ship Pi­o­neer­ing start­up, work­ing with Quo­tient Ther­a­peu­tics to iden­ti­fy ge­net­ic mu­ta­tions that arise by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Ar­bor Biotech­nolo­gies cuts ear­ly-stage dis­cov­ery work, lays off staff

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

Af­ter a huge IPO and ac­qui­si­tion, Zymer­gen caps off bank­rupt­cy with $30M SEC penal­ty

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board

A service from the Financial Times